The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Blood

Volumn 121, Issue 4, 2013, Pages 628-637

  Giannoudis, Athina ^a   Wang, Lihui ^a   Jorgensen, Andrea L ^a   Xinarianos, George ^a   Davies, Andrea ^a   Pushpakom, Sudeep ^a   Liloglou, Triantafilos ^a   Zhang, Jieying Eunice ^a   Austin, Gemma ^a   Holyoake, Tessa L ^b   Foroni, Letizia ^c   Kottaridis, Panagiotis D ^d   Müller, Martin C ^e   Pirmohamed, Munir ^a   Clark, Richard E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN ORGANIC CATION TRANSPORTER 1; IMATINIB; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG UPTAKE; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC TRANSFECTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS ARRAY SEQUENCING; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROTEIN DETERMINATION; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84873032664     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-405035     Document Type: Article

References (33)

1. Thomas J, Wang L, Clark RE, Pirmohammed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004; 104(12):3739-3745.
2. White DL, Dang P, Engler J, et al. Functional activity of the OCT1 protein is predictive of long term outcome in patients with chronic phase chronic myeloid leukaemia treated with imatinib. J Clin Oncol. 2010;28(16):2761-2767.
3. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important determinant of the response to imatinib in chronic myeloid leukaemia. Clin Pharm Therap. 2008; 83(2):258-264.
4. Larson RA, Hochhaus A, Hughes TP, et al. Nilo-tinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year follow-up. Leukemia. 2012; 26(10):2197-2203.
5. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.
6. Lucas CM, Wang L, Austin GM, et al.A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10):1963-1966.
7. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
8. Gallipoli P, Shepherd P, Irvine D, Drummond M, Holyoake TL. Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. Br J Haematol. 2011;155(1):128-130.
9. Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002;12(8): 591-595.
10. Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Comm. 2004;313(3): 789-793.
11. Ahlin G, Chen L, Lazorova L, et al. Genotype dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2011;11(6):400-411.
12. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422-1431.
13. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharm Therap. 2008;83(2):273-280.
14. Kim DHD, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to matinib therapy in chronic myeloid leukaemia. Clin Cancer Res. 2009;15(14):4750-4758.
15. Bazeos A, Marin D, Reid AG, et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukaemia. Leukemia. 2010; 24(6):1243-1245.
16. White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT1. Leukemia. 2010;24(11):1962-1965.
17. Maffioli M, Camós M, Gaya A, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res. 2011;35(8): 1014-1019.
18. Zhang EJ, Jorgensen AL, Alfirevic A, et al. Effects of CYP4F2 genetic polymorphisms and haplo-types on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics. 2009;19(10):781-789.
19. Giannoudis A, Davies A, Lucas C, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008;112(8):3348-3354.
20. White DL, Saunders VA, Dang P, et al: Most CML patients who have a suboptimal response to ima-tinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110(12):4064-4072.
21. Biermann J, Lang D, Gorboulev V, et al. Characterisation of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006;290(6):C1521-C1531.
22. Dickens D, Owen A, Alfirevic A, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharm. 2012;83(6):805-814.
23. Therneau T. A package for survival analysis in S. 2012. R Package Version 2.36-12.
24. Gray RJ. A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
25. Gray B. Package 'cmprsk': Subdistribution analysis of competing risks. R Package Version 2.2-2. Available from: http://CRAN.R-project.org/package=cmprsk.
26. Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A. 2003;100(10):5902-5907.
27. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
28. Chen L, Takizawa M, Chen E, et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 2010; 335(1):42-50.
29. Zhou K, Donnelly LA, Kimber CH, et al. Reduced function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study. Diabetes. 2009; 58(6):1434-1439.
30. Zach O, Krieger O, Foedermayer M, Zellhofer B, Lutz D. R61C polymorphism and response to imatinib treatment in chronic myeloid leukaemia patients. Leuk Lymphoma. 2008;49(11):2222-2223.
31. Davies A, Jordanides N, Giannoudis A, et al. Nilo-tinib concentration in cell lines and CD34+ CML cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009;23(11): 1999-2006.
32. Ciarimboli C, Koepsell H, Iordanova M, et al. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol. 2005;16(6):1562-1570.
33. Gambineri A, Tomassoni F, Gasparini DI, et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95(10):E204-E208.